Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study
Andrew Schmidt(Dana-Farber Cancer Institute), Deborah B. Doroshow(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Catherine Curran(Dana-Farber Cancer Institute), Alaina J. Kessler(Icahn School of Medicine at Mount Sinai), Michelle Evans(Mount Sinai Hospital), Gabrielle Bouchard(Dana-Farber Cancer Institute), Ziad Bakouny(Dana-Farber Cancer Institute), Brittney S. Zimmerman(Icahn School of Medicine at Mount Sinai), Sheena Bhalla(Icahn School of Medicine at Mount Sinai), Fiona Busser(Dana-Farber Cancer Institute), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Laure Hirsch(Harvard University), Toni K. Choueiri(Harvard University), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Tomi Jun(Sema4 (United States)), Kaitlin M. Kelleher(Dana-Farber Cancer Institute), Hsin-Hui Huang(Icahn School of Medicine at Mount Sinai), Jonathan Feld(Icahn School of Medicine at Mount Sinai), Michael Wotman(The University of Texas MD Anderson Cancer Center), Penina S. Stewart(Icahn School of Medicine at Mount Sinai), Robert I. Haddad(Georgetown University), Douglas Tremblay(Icahn School of Medicine at Mount Sinai), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Danielle Seidman(Icahn School of Medicine at Mount Sinai), Talia D. Rosenbloom(Icahn School of Medicine at Mount Sinai), Sarah Abou Alaiwi(Yale New Haven Hospital), Heather Anderson-Keightly(Icahn School of Medicine at Mount Sinai), Qian Qin(Icahn School of Medicine at Mount Sinai)
Cited by 72
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k